

Understanding the Medicare Drug Price Negotiation Program (MDPNP)

In August 2022, the Inflation Reduction Act (P.L. 117-169) was signed into law. For the first time, the law provides Medicare the ability to directly negotiate the prices of certain high expenditure, single source Medicare Part B and Part D drugs without generic or biosimilar competition through the Medicare Drug Price Negotiation Program (MDPNP). These negotiated prices, referred to as Maximum Fair Prices (MFPs), are based on negotiations and agreements reached between the Centers for Medicare & Medicaid Services (CMS) and participating drug manufacturers.

In August 2023, CMS selected 10 drugs covered under Medicare Part D for the first cycle of negotiations with MFPs going into effect in 2026. In January 2025, CMS announced the selection of 15 additional drugs covered under Medicare Part D for the second cycle of negotiations with MFPs expected to go into effect in 2027.

First round of Medicare Part D drugs selected for negotiated pricing effective January 1, 2026

- Eliquis®
- Enbrel®
- Entresto®
- Farxiga®
- Fiasp®; Fiasp® FlexTouch; Fiasp® PenFill; NovoLog®; NovoLog® Flexpen; NovoLog® PenFill
- Imbruvica®
- Januvia®
- Jardiance®
- Stelara®
- Xarelto®

CMS fact sheet

To view 2026 MFP drugs or learn more about CMS' negotiation process for the drugs listed above, scan or click the QR code.



Second round of Medicare Part D drugs selected for negotiated pricing effective January 1, 2027

- Austedo®; Austedo XR®
- Breo Ellipta
- Calquence®
- Ibrance®
- Janumet®; Janumet® XR
- Linzess®
- Ofev®
- Otezla®
- Ozempic®; Rybelsus®; Wegovy®
- Pomalyst®
- Tradjenta®
- Treligy Ellipta
- Vraylar®
- Xifaxan®

The deadline for CMS to publish agreed-upon MFPs for the drugs listed above is November 30, 2025.

CMS press release

To learn more about CMS' selection process for the drugs listed above or key milestones for the second cycle of negotiations, scan or click the QR code.



Medicare Drug Price Negotiation Program: Key milestones through 2027

2023

August 29

CMS announced 10 Medicare Part D drugs selected for first round of negotiations

2024

August 1

First negotiation period between CMS and participating drug manufacturers ends

August 15

CMS published maximum fair prices for first round of selected drugs effective 2026

2025

January 17

CMS announced 15 more Medicare Part D drugs selected for second round of negotiations

Spring

CMS intends to release draft guidance for the third cycle of negotiations with MFP effective in 2028, including new policies on renegotiation and Part B drugs

Fall/Winter

CMS intends to release final guidance on third cycle of negotiations with MFP effective in 2028, including new policies on renegotiation and Part B drugs

November 1

Second negotiation period between CMS and participating drug manufacturers ends

November 30

Deadline for CMS to publish the maximum fair prices for second round of selected drugs effective 2027

2026

January 1

Maximum fair prices are effective for the first round of drugs selected in 2023

March 1

Deadline for CMS to publish explanations of agreed-upon MFPs for the second rounds of selected drugs

2027

January 1

Maximum fair prices are effective for the second round of drugs selected in 2025